Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com to a "sell" rating.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $41.00. They now have an "overweight" rating on the stock.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)